Adicet Bio Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-38359 Adicet Bio, Inc. (Exact name of registrant as specified in its charter) 81-3305277(I.R.S. EmployerIdentification No.) Delaware(State or other jurisdiction ofincorporation or organization) 131 Dartmouth Street, 3rd FloorBoston, MA(Address of principal executive offices) 02116(Zip Code) (650) 503-9095(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ Accelerated filer☐Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May 11, 2026, the registrant had 9,348,236 shares of common stock, $0.0001 par value per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATION5Item 1.Consolidated Financial Statements (Unaudited)5Consolidated Balance Sheets as of March 31, 2026 and December 31, 20255Consolidated Statements of Operations and Comprehensive Loss for the Three Months ended March 31, 2026 and20256Consolidated Statements of Stockholders’ Equity for the Three Months ended March 31, 2026 and 20257Consolidated Statements of Cash Flows for the Three Months ended March 31, 2026 and 20259Notes to Unaudited Consolidated Financial Statements10Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations24Item 3.Quantitative and Qualitative Disclosures About Market Risk31Item 4.Controls and Procedures32PART II.OTHER INFORMATION33Item 1.Legal Proceedings33Item 1A.Risk Factors33Item 2.Unregistered Sales of Equity Securities and Use of Proceeds85Item 3.Defaults Upon Senior Securities85Item 4.Mine Safety Disclosures85Item 5.Other Information85Item 6.Exhibits85Signatures87 Summary of the Material Risks Associated with Our Business •We have a limited operating history and face significant challenges and expenses as we build our capabilities.•Our business is highly dependent on the success of prula-cel (formerly ADI-001). If we are unable to obtain regulatoryapproval for prula-cel in one or more indications and effectively commercialize this product candidate for the treatmentof patients in indications for which we receive approval (if any), our business would be significantly harmed.•Our gamma delta T cell candidates represent a novel approach to the treatment of autoimmune diseases and cancerindications that creates significant challenges for us.•Our product candidates are based on novel technologies, which makes it difficult to predict the likely success of suchproduct candidates and the time and cost of product candidate development and obtaining regulatory approval.•Our clinical trials may fail to demonstrate the safety and efficacy of any of our product candidates, which wouldprevent or delay regulatory approval and commercialization.•We may not be able to file Investigational New Drug (IND) applications, or comparable regulatory submissions, tocommence additional clinical trials on the timelines we expect, and even if we are able to, the U.S. Food and DrugAdministration (FDA) or analogous regulatory authorities may not permit us to proceed.•We may encounter substantial delays in our clinical trials, or may not be able to conduct our trials on the timelines weexpect.•The market opportunities for our product candidates may be limited to those patients who are ineligible for or havefailed prior treatm